3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neuralgia
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lung Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Leucovorin
22
Fluorouracil
22
Gemcitabine
21
Capecitabine
21
Paclitaxel
20
Docetaxel
20
Irinotecan
15
Carboplatin
15
Radiosurgery
14
Oxaliplatin
13
Cisplatin
13
Bevacizumab
13
Zoledronic Acid
12
pembrolizumab
11
Radiotherapy
11
Fulvestrant
11
palbociclib
9
Pemetrexed
9
Drug Therapy
9
130-nm albumin-bound paclitaxel
9
Surgical Procedures, Operative
7
Letrozole
7
Ibandronic Acid
7
abemaciclib
6
Trastuzumab
6
Prednisone
6
Vinorelbine
5
Folfox protocol
5
Floxuridine
5
Doxorubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasm Metastasis
×
Vitamin B 12
×
Clear all
NCT04786964
2025-04-02
CONTERNO
Checkpoint Therapeutics, Inc.
Phase 3
Terminated
25 enrolled
10 charts